Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review
Open Access
- 1 September 2025
- journal article
- review article
- Published by Wolters Kluwer Health in International Journal of Preventive Medicine
- Vol. 16
Abstract
Background: Obesity imposes a heavy burden on healthcare systems and society. Despite various treatment options, choosing cost-effective pharmacological interventions remains a key concern for health policymakers. This study systematically reviews economic evaluations of antiobesity drugs, comparing their costs and outcomes with those of lifestyle interventions. Methods: A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Four databases (PubMed, Scopus, Web of Science, and Embase) were searched for full economic evaluations of FDA-approved antiobesity drugs, including semaglutide, liraglutide, tirzepatide, phentermine-topiramate, and orlistat. Inclusion criteria required studies to report cost-effectiveness, cost-utility, or cost-benefit outcomes. Data on incremental cost-effectiveness ratios (ICERs), quality-adjusted life years (QALY), or disability-adjusted life years (DALY) were extracted and adjusted to 2024 USD using PPP. Study quality was assessed using CHEERS 2022. Results: Fifteen studies met the inclusion criteria. Most used Markov models and cost-effectiveness analyses. The review of articles showed that 60% of the articles were conducted in the United States of America, 33.33% of the articles in Europe, and 6.66% of the articles in Australia. Among the reviewed studies, semaglutide was found to be the most cost-effective and clinically effective drug in most scenarios. Phentermine-topiramate showed acceptable cost-effectiveness, particularly in low-resource settings. Orlistat and naltrexone-bupropion were also considered affordable options, though with lower effectiveness. Tirzepatide, despite its high efficacy, demonstrated a higher ICER, making its cost-effectiveness context-dependent. Conclusions: These findings highlight the importance of integrating cost-effective pharmacological treatments into obesity management strategies. Semaglutide appears to be a highly effective and economically favorable option, while phentermine-topiramate and orlistat offer practical alternatives in resource-limited settings. Economic evaluations can inform policy decisions and optimize healthcare resource allocation in combating obesity.Keywords
This publication has 33 references indexed in Scilit:
- Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United KingdomApplied Health Economics and Health Policy, 2023
- Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe ObesityJAMA Network Open, 2023
- Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in AdolescentsJAMA Network Open, 2023
- Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspectiveNutrition, Metabolism and Cardiovascular Diseases, 2023
- The cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesityObesity Science & Practice, 2019
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptMolecular Metabolism, 2018
- Associations of Weight Gain From Early to Middle Adulthood With Major Health Outcomes Later in LifeJAMA, 2017
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse EventsJAMA, 2016
- Cost-Effectiveness Analysis of Qsymia for Weight LossPharmacoEconomics, 2014
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in AdultsJACC, 2014